DK3686288T3 - Fremgangsmåder og materialer til analyse af homolog rekombinationsdeficiens - Google Patents

Fremgangsmåder og materialer til analyse af homolog rekombinationsdeficiens Download PDF

Info

Publication number
DK3686288T3
DK3686288T3 DK20162059.8T DK20162059T DK3686288T3 DK 3686288 T3 DK3686288 T3 DK 3686288T3 DK 20162059 T DK20162059 T DK 20162059T DK 3686288 T3 DK3686288 T3 DK 3686288T3
Authority
DK
Denmark
Prior art keywords
analysis
materials
methods
homologous recombination
recombination deficiency
Prior art date
Application number
DK20162059.8T
Other languages
English (en)
Inventor
Victor Abkevich
Kirsten Timms
Alexander Gutin
Julia Reid
Original Assignee
Myriad Genetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54035301&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3686288(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Myriad Genetics Inc filed Critical Myriad Genetics Inc
Application granted granted Critical
Publication of DK3686288T3 publication Critical patent/DK3686288T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Catalysts (AREA)
  • Carbon And Carbon Compounds (AREA)
DK20162059.8T 2014-08-15 2015-08-17 Fremgangsmåder og materialer til analyse af homolog rekombinationsdeficiens DK3686288T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462037764P 2014-08-15 2014-08-15
US201414507412A 2014-10-06 2014-10-06
EP15757372.6A EP3180447B1 (en) 2014-08-15 2015-08-17 Methods and materials for assessing homologous recombination deficiency

Publications (1)

Publication Number Publication Date
DK3686288T3 true DK3686288T3 (da) 2023-05-22

Family

ID=54035301

Family Applications (3)

Application Number Title Priority Date Filing Date
DK23160447.1T DK4234711T3 (da) 2014-08-15 2015-08-17 Fremgangsmåder og materialer til vurdering af mangel på homolog rekombination
DK20162059.8T DK3686288T3 (da) 2014-08-15 2015-08-17 Fremgangsmåder og materialer til analyse af homolog rekombinationsdeficiens
DK15757372.6T DK3180447T3 (da) 2014-08-15 2015-08-17 Fremgangsmåder og materialer til analyse af homolog rekombinationsdeficiens

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK23160447.1T DK4234711T3 (da) 2014-08-15 2015-08-17 Fremgangsmåder og materialer til vurdering af mangel på homolog rekombination

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK15757372.6T DK3180447T3 (da) 2014-08-15 2015-08-17 Fremgangsmåder og materialer til analyse af homolog rekombinationsdeficiens

Country Status (9)

Country Link
US (4) US10400287B2 (da)
EP (4) EP3180447B1 (da)
JP (4) JP6877334B2 (da)
AU (2) AU2015301390B2 (da)
CA (1) CA2958801A1 (da)
DK (3) DK4234711T3 (da)
ES (3) ES2946251T3 (da)
PT (1) PT3180447T (da)
WO (1) WO2016025958A1 (da)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014015152A2 (pt) * 2011-12-21 2017-07-04 Myriad Genetics Inc métodos e materiais para a avaliação da perda de heterozigosidade
PL4574996T3 (pl) * 2014-12-31 2026-03-02 Guardant Health, Inc. Wykrywanie i leczenie chorób wykazujących heterogeniczność komórek chorobowych oraz systemy i sposoby przekazywania wyników testów
MX2018010223A (es) * 2016-02-29 2018-11-09 Synta Pharmaceuticals Corp Terapia combinada para tratamiento de cancer de ovario.
WO2017178509A1 (en) * 2016-04-12 2017-10-19 Xentech Methods for predicting sensibility to treatment with parp inhibitors in cancerous patients
EP3452937B1 (en) 2016-05-01 2025-10-22 Genome Research Limited Method of characterising a dna sample
US12537074B2 (en) 2016-05-01 2026-01-27 Genome Research Limited Method of characterising a DNA sample
WO2018162439A1 (en) * 2017-03-08 2018-09-13 Onxeo New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule
CN108663519A (zh) * 2017-04-21 2018-10-16 江苏希摩生物科技有限公司 快速预测和提高BRCA1/2野生型卵巢癌细胞对Olaparib敏感性的方法
US20200239969A1 (en) * 2017-10-16 2020-07-30 The Board Of Regents Of The University Of Texas System Methods and compositions for use of trex2 as diagnostic and prognostic marker for cancer
AU2020221845A1 (en) * 2019-02-12 2021-09-02 Tempus Ai, Inc. An integrated machine-learning framework to estimate homologous recombination deficiency
WO2021011507A1 (en) * 2019-07-12 2021-01-21 Tempus Labs Adaptive order fulfillment and tracking methods and systems
US20240079108A1 (en) * 2019-10-09 2024-03-07 Immunitybio, Inc. Detecting Homologous Recombination Deficiencies (HRD) in Clinical Samples
AU2020398913A1 (en) 2019-12-10 2022-06-16 Tempus Ai, Inc. Systems and methods for predicting homologous recombination deficiency status of a specimen
US12241126B2 (en) 2020-05-14 2025-03-04 Guardant Health, Inc. Homologous recombination repair deficiency detection
EP3945525A1 (en) 2020-07-27 2022-02-02 Sophia Genetics S.A. Methods for identifying chromosomal spatial instability such as homologous repair deficiency in low coverage next-generation sequencing data
CN112164420B (zh) 2020-09-07 2021-07-20 厦门艾德生物医药科技股份有限公司 一种基因组瘢痕模型的建立方法
CN112410423B (zh) * 2020-11-03 2021-08-13 南京世和基因生物技术股份有限公司 同源重组缺失的标志物、检测方法以及检测系统
CN112397145A (zh) * 2020-11-19 2021-02-23 河南省肿瘤医院 一种基于芯片检测的hrd评分计算方法
JP7585015B2 (ja) 2020-12-04 2024-11-18 株式会社東芝 核酸構築物のセット、キット、検出方法及び薬剤効果予測方法
JP7696647B2 (ja) * 2021-01-10 2025-06-23 エーシーティー ジェノミックス （アイピー） リミテッド 相同組換え修復欠損を判定する方法及びそのキット
WO2022150063A1 (en) * 2021-01-10 2022-07-14 Act Genomics (Ip) Co., Ltd. Homologous recombination deficiency determining method and kit thereof
CN112820351A (zh) * 2021-03-01 2021-05-18 江苏医联生物科技有限公司 检测肿瘤患者的突变和hrd评分指导用药的方法
CN112980834B (zh) * 2021-04-22 2021-08-17 菁良基因科技(深圳)有限公司 一种同源重组修复缺陷参考品及其制备方法和试剂盒
CN113257346B (zh) * 2021-06-28 2021-10-19 北京橡鑫生物科技有限公司 一种基于低深度WGS评估HRD score的方法
CN113658638B (zh) * 2021-08-20 2022-06-03 江苏先声医学诊断有限公司 一种基于ngs平台的同源重组缺陷的检测方法和质控体系
CN113462784B (zh) * 2021-08-31 2021-12-10 迈杰转化医学研究(苏州)有限公司 一种构建用于同源重组修复缺陷检测的靶标集合的方法
TWI861616B (zh) * 2021-12-08 2024-11-11 美商米瑞德遺傳學公司 用於評估乳癌亞型中同源重組缺陷之方法及材料
CN114242170B (zh) * 2021-12-21 2023-05-09 深圳吉因加医学检验实验室 一种同源重组修复缺陷的评估方法、装置和存储介质
CN114283889B (zh) * 2021-12-27 2024-12-10 深圳吉因加医学检验实验室 一种矫正同源重组修复缺陷评分的方法及装置
KR102523938B1 (ko) * 2022-02-04 2023-04-19 가톨릭대학교 산학협력단 상동 재조합 결핍증 예측 모델의 모델링 방법
WO2024083971A1 (en) 2022-10-19 2024-04-25 Vib Vzw Method of determining loss of heterozygosity status of a tumor
WO2025078404A1 (en) 2023-10-10 2025-04-17 Vib Vzw Methods of determining response of a tumor to dna-damaging agents or to agents inhibiting or impairing dna repair
WO2025078387A1 (en) 2023-10-10 2025-04-17 Vib Vzw Method of detecting loss of heterozygosity status of a tumor
WO2025173014A1 (en) 2024-02-16 2025-08-21 Onecell Diagnostics India Private Limited A method for selecting ovarian cancer patients for parp inhibitor treatment

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU33730B (en) 1967-04-18 1978-02-28 Farmaceutici Italia Process for preparing a novel antibiotic substance and salts thereof
GB1432563A (en) 1972-04-10 1976-04-22 Rustenburg Platinum Mines Ltd Platinum- co-ordination compounds
GB1432562A (en) 1972-04-10 1976-04-22 Rustenburg Platinum Mines Ltd Platinum co-ordination compounds
ES444380A1 (es) 1976-01-16 1977-06-16 Gosalvez Mario Un procedimiento para preparar derivados metalicos antraci- clinicos.
US4950738A (en) 1984-09-13 1990-08-21 Cytogen Corporation Amine derivatives of anthracycline antibiotics
US5977082A (en) 1985-08-02 1999-11-02 Pharmacia & Upjohn Company Injectable ready-to-use solutions containing an antitumor anthracycline glycoside
DE3630497A1 (de) 1986-09-08 1988-03-10 Behringwerke Ag Cis-platin-komplexe, verfahren zu ihrer herstellung und diese verbindungen enthaltende pharmazeutische mittel
FI87572C (fi) 1987-05-08 1993-01-25 Sankyo Co Foerfarande foer framstaellning av platinakomplex med terapeutisk effekt
US4996337A (en) 1987-06-23 1991-02-26 American Cyanamid Company Synthesis of cisplatin analogs
US5177075A (en) 1988-08-19 1993-01-05 Warner-Lambert Company Substituted dihydroisoquinolinones and related compounds as potentiators of the lethal effects of radiation and certain chemotherapeutic agents; selected compounds, analogs and process
US5434256A (en) 1988-11-22 1995-07-18 Board Of Regents, The University Of Texas System Diamine platinum complexes as antitumor agents
US4946954A (en) 1989-01-17 1990-08-07 Georgetown University Platinum pharmaceutical agents
US5744101A (en) 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
US6040138A (en) 1995-09-15 2000-03-21 Affymetrix, Inc. Expression monitoring by hybridization to high density oligonucleotide arrays
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
AU647741B2 (en) 1989-12-01 1994-03-31 Regents Of The University Of California, The Methods and compositions for chromosome-specific staining
US5214821A (en) 1991-05-07 1993-06-01 The Morgan Crucible Company Plc Low contamination swab employing tubular knit fabric
US5295944A (en) 1991-05-14 1994-03-22 Dana-Farber Cancer Institute Method for treating a tumor with ionizing radiation
WO1993009782A1 (en) 1991-11-15 1993-05-27 Smithkline Beecham Corporation Combination chemotherapy
US5587384A (en) 1994-02-04 1996-12-24 The Johns Hopkins University Inhibitors of poly(ADP-ribose) synthetase and use thereof to treat NMDA neurotoxicity
US5578832A (en) 1994-09-02 1996-11-26 Affymetrix, Inc. Method and apparatus for imaging a sample on a device
US5539083A (en) 1994-02-23 1996-07-23 Isis Pharmaceuticals, Inc. Peptide nucleic acid combinatorial libraries and improved methods of synthesis
US5556752A (en) 1994-10-24 1996-09-17 Affymetrix, Inc. Surface-bound, unimolecular, double-stranded DNA
US5837492A (en) 1995-12-18 1998-11-17 Myriad Genetics, Inc. Chromosome 13-linked breast cancer susceptibility gene
GB9620209D0 (en) 1996-09-27 1996-11-13 Cemu Bioteknik Ab Method of sequencing DNA
GB9626815D0 (en) 1996-12-23 1997-02-12 Cemu Bioteknik Ab Method of sequencing DNA
CA2284211A1 (en) 1997-03-20 1998-09-24 University Of Washington Solvent for biopolymer synthesis, solvent microdroplets and methods of use
US6214821B1 (en) 1998-03-05 2001-04-10 Washington State University Research Foundation Methods and composition for the inhibition of cancer cells
GB9806324D0 (en) 1998-03-24 1998-05-20 Pharmacia & Upjohn Spa Antitumour synergetic composition
GB9808145D0 (en) 1998-04-17 1998-06-17 Zeneca Ltd Assay
WO2000009759A1 (en) 1998-08-17 2000-02-24 The Burnham Institute Methods for identifying somatic changes in genomic sequences useful for cancer diagnosis and prognosis
US6465177B1 (en) 1998-10-26 2002-10-15 John Wayne Cancer Institute Detection of loss of heterozygosity in tumor and serum of melanoma patients
EP1141384A2 (en) 1999-01-06 2001-10-10 Cornell Research Foundation, Inc. Method for accelerating identification of single nucleotide polymorphisms and alignment of clones in genomic sequencing
US6261775B1 (en) 1999-04-09 2001-07-17 The Regents Of The University Of California Detection of chromosome copy number changes to distinguish melanocytic nevi from malignant melanoma
US6274320B1 (en) 1999-09-16 2001-08-14 Curagen Corporation Method of sequencing a nucleic acid
US7858331B2 (en) 2000-11-03 2010-12-28 Dana Farber Cancer Institute, Inc. Compositions and methods for the treatment of cancer
MXPA03004832A (es) 2000-12-01 2004-05-04 Guilford Pharm Inc Compuestos y sus usos.
GB0121285D0 (en) 2001-09-03 2001-10-24 Cancer Res Ventures Ltd Anti-cancer combinations
NZ535044A (en) 2002-03-01 2008-12-24 Ravgen Inc Non-invasive method to determine the genetic sequence of foetal DNA from a sample from a pregnant female thereby detecting any alternation in gene sequence as compared with the wild type sequence
WO2004042032A2 (en) 2002-11-01 2004-05-21 The Ohio State University Research Foundation Cytogenetic abnormalities that are predictive of response to therapy for chronic lymphocytic leukemia
US20070004621A1 (en) 2003-02-12 2007-01-04 Viji Shridhar Bex4 nucleic acids, polypeptides, and method of using
US20040170983A1 (en) 2003-02-27 2004-09-02 Danenberg Kathleen D. Methods of determining a chemotherapuetic regimin based on loss of heterozygosity at the thymidylate synthase locus
WO2004083816A2 (en) 2003-03-14 2004-09-30 John Wayne Cancer Institute Loss of heterozygosity of the dna markers in the 12q22-23 region
WO2005002508A2 (en) 2003-06-11 2005-01-13 Access Pharmaceuticals, Inc. Macromolecular platinum chelates
DE04777189T1 (de) 2003-07-02 2011-04-07 Solux Corporation, San Diego Thermisch stabiles kristallines epirubicin-hydrochlorid und herstellungsverfahren dafür
PL1660095T3 (pl) 2003-07-25 2010-07-30 Cancer Research Tech Ltd Tricykliczne inhibitory PARP
JP2007502301A (ja) 2003-08-13 2007-02-08 ユニバーシティー オブ サウス フロリダ 腫瘍細胞の増殖を阻害するための方法
US20080108057A1 (en) 2004-06-22 2008-05-08 Griffith Jeffrey K Allelic imbalance in the diagnosis and prognosis of cancer
US7860840B2 (en) 2004-10-05 2010-12-28 Microsoft Corporation Maintaining correct transaction results when transaction management configurations change
CA2585025A1 (en) 2004-10-22 2006-05-04 Redpath Integrated Pathology, Inc. Dynamic genomic deletion expansion and formulation of molecular marker panels for integrated molecular pathology diagnosis and characterization of tissue, cellular fluid, and purefluid specimens
US20070070349A1 (en) 2005-09-23 2007-03-29 Helicos Biosciences Corporation Optical train and method for TIRF single molecule detection and analysis
WO2006098978A1 (en) 2005-03-09 2006-09-21 Abbott Laboratories Diagnostics method for identifying candidate patients for the treatment with trastuzumab
EP1877576B1 (en) 2005-04-12 2013-01-23 454 Life Sciences Corporation Methods for determining sequence variants using ultra-deep sequencing
BRPI0609939A2 (pt) 2005-04-21 2010-05-11 Alza Corp método para tratar cáncer de ovário avançado com doxorubicina capturada em lipossomas
WO2006128195A2 (en) 2005-05-27 2006-11-30 Dana-Farber Cancer Institute Methods of diagnosing and treating cancer by detection of chromosomal abnormalities
JP5193032B2 (ja) 2005-06-30 2013-05-08 バイオニューメリック・ファーマスーティカルズ・インコーポレイテッド モノアゾールリガンド白金類似体
WO2007035893A2 (en) 2005-09-21 2007-03-29 Bioarray Solutions, Ltd. Use of ivt with single stranded primer promoter selector constructs
US20080262062A1 (en) 2006-11-20 2008-10-23 Bipar Sciences, Inc. Method of treating diseases with parp inhibitors
WO2008112193A1 (en) 2007-03-12 2008-09-18 Dana-Farber Cancer Institute Prognostic, diagnostic, and cancer therapeutic uses of fanci and fanci modulating agents
JP5707132B2 (ja) 2007-09-07 2015-04-22 フルイダイム コーポレイション コピー数変動の決定、方法およびシステム
JP2011503111A (ja) 2007-11-12 2011-01-27 バイパー サイエンシズ，インコーポレイティド Ｐａｒｐ阻害剤単独又は抗腫瘍剤との組み合わせによる乳がんの治療
KR20100102637A (ko) 2007-12-07 2010-09-24 바이파 사이언스 인코포레이티드 토포이소머라제 억제제 및 ｐａｒｐ 억제제의 병용물에 의한 암의 치료
US20090246789A1 (en) 2008-03-25 2009-10-01 University Of South Carolina Gene Mutation Profiling of CSMD1
US20100086922A1 (en) 2008-05-30 2010-04-08 Millennium Pharmaceuticals, Inc. Assessment of chromosomal alterations to predict clinical outcome of bortezomib treatment
US8583380B2 (en) 2008-09-05 2013-11-12 Aueon, Inc. Methods for stratifying and annotating cancer drug treatment options
CA2739459A1 (en) 2008-10-31 2010-05-06 Abbott Laboratories Genomic classification of colorectal cancer based on patterns of gene copy number alterations
US10262103B2 (en) 2008-11-18 2019-04-16 Raphael LEHRER Individualized cancer treatment
US8206910B2 (en) 2008-12-08 2012-06-26 The Cleveland Clinic Foundation Targets for use in diagnosis, prognosis and therapy of breast cancer
KR100925337B1 (ko) 2009-05-25 2009-11-09 주식회사 마크로젠 염색체 수 이상 검출을 통한 유방암 약물 반응성 예측
WO2011048495A1 (en) 2009-10-19 2011-04-28 Stichting Het Nederlands Kanker Instituut Predicting benefit of anti-cancer therapy via array comparative genomic hybridization
US20130079423A1 (en) 2010-02-24 2013-03-28 Myriad Genetics, Incorporated Diagnostic methods involving loss of heterozygosity
DK3012329T3 (da) 2010-06-18 2017-11-20 Myriad Genetics Inc Fremgangsmåder og materialer til at vurdere tab af heterozygositet
WO2012019000A2 (en) 2010-08-04 2012-02-09 On-Q-ity Biomarkers for the identification monitoring and treatment of ovarian cancer
DK2609216T3 (da) 2010-08-24 2016-09-12 Dana Farber Cancer Inst Inc Fremgangsmåder til at forudsige antikræftreaktion
KR20140024270A (ko) 2010-12-30 2014-02-28 파운데이션 메디신 인코포레이티드 종양 샘플의 다유전자 분석의 최적화
EP3693473B1 (en) 2011-06-17 2025-02-19 Myriad Genetics, Inc. Methods and materials for assessing allelic imbalance
BR112014015152A2 (pt) * 2011-12-21 2017-07-04 Myriad Genetics Inc métodos e materiais para a avaliação da perda de heterozigosidade
DK3415915T3 (da) * 2012-02-23 2024-11-04 Childrens Medical Center Fremgangsmåde til at forudsige respons til PARP-inhibitorer
AU2013273466B2 (en) 2012-06-07 2018-11-01 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods for detecting inactivation of the homologous recombination pathway (BRCA1/2) in human tumors
DK2981624T3 (da) 2013-04-05 2020-03-02 Myriad Genetics Inc Fremgangsmåder til vurdering af homolog rekombinationsdeficiens og forudsigelse af respons på cancerbehandling
WO2015086473A1 (en) 2013-12-09 2015-06-18 Institut Curie Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors
US20180163271A1 (en) 2014-01-16 2018-06-14 Clovis Oncology, Inc. Use of PARP Inhibitors to Treat Breast or Ovarian Cancer Patients Showing a Loss of Heterozygosity

Also Published As

Publication number Publication date
JP2017533693A (ja) 2017-11-16
AU2021273600B2 (en) 2025-02-13
WO2016025958A1 (en) 2016-02-18
CA2958801A1 (en) 2016-02-18
AU2015301390A1 (en) 2017-02-02
EP3180447A1 (en) 2017-06-21
ES2946251T3 (es) 2023-07-14
EP4585701A2 (en) 2025-07-16
US12221656B2 (en) 2025-02-11
EP3686288B1 (en) 2023-03-08
US20190185939A1 (en) 2019-06-20
ES3039109T3 (en) 2025-10-17
AU2021273600A1 (en) 2021-12-16
EP4234711A2 (en) 2023-08-30
PT3180447T (pt) 2020-06-18
EP4234711B1 (en) 2025-05-28
US20170283879A1 (en) 2017-10-05
US12421555B2 (en) 2025-09-23
EP4585701A3 (en) 2025-08-06
NZ728326A (en) 2024-08-30
JP7680995B2 (ja) 2025-05-21
US20250179587A1 (en) 2025-06-05
US10400287B2 (en) 2019-09-03
AU2015301390B2 (en) 2021-08-26
JP2021112205A (ja) 2021-08-05
JP2023015394A (ja) 2023-01-31
JP2025114740A (ja) 2025-08-05
JP6877334B2 (ja) 2021-05-26
US20230117133A1 (en) 2023-04-20
DK3180447T3 (da) 2020-06-15
DK4234711T3 (da) 2025-08-25
ES2800673T3 (es) 2021-01-04
NZ766822A (en) 2024-08-30
EP4234711A3 (en) 2023-09-20
EP3686288A1 (en) 2020-07-29
EP3180447B1 (en) 2020-03-11
JP7229297B2 (ja) 2023-02-27

Similar Documents

Publication Publication Date Title
DK3180447T3 (da) Fremgangsmåder og materialer til analyse af homolog rekombinationsdeficiens
DK3201351T3 (da) Kaloriefrie sødestoffer og fremgangsmåder til syntetisering
IL251972B (en) Analyzing and utilizing landscapes
IL254734B1 (en) Modified t cells and methods of making and using the same
IL299926A (en) Neoantigens and methods of their use
DK3538864T3 (da) Mikrotom
DK3134149T3 (da) Mikrokanyler og fremgangsmåder til fremstilling deraf
DK3227336T3 (da) Anti-CD79b-antistoffer og fremgangsmåder til anvendelse
DK3215147T3 (da) Neurodæmpende norketamin-forbindelser og fremgangsmåder
EP3350508A4 (en) ARTIFICIAL ROOF WINDOW AND METHOD
DK3215601T3 (da) Fremgangsmåder til transduktion og celleforarbejdning
PL3480213T3 (pl) Polipeptydy syntac i ich zastosowania
DK3384274T3 (da) Fremgangsmåder til prøvekarakterisering
DK3108009T3 (da) Fremgangsmåder og sammensætninger til DNA-profilering
DK3492632T3 (da) Metoder til behandling af lithiumholdige materialer
DK3161124T3 (da) Endofytter, associerede sammensætninger og fremgangsmåder til anvendelse deraf
DK3792378T3 (da) Fremgangsmåder og anordninger til analyse af partikler
DK2924093T3 (da) Multicarboxylat-sammensætninger og fremgangsmåde til fremstilling af disse
DK3089971T3 (da) Forbindelser og fremgangsmåder til anvendelse
PL3123166T3 (pl) Wlot detektora i sposób próbkowania
HUE060552T2 (hu) Lemezvizsgáló berendezés
DK3123177T3 (da) Prøveselektor
EP2998732C0 (en) ANALYSIS PROCESS
DK3240684T3 (da) Byggemateriale
IL246642A0 (en) Materials and methods for quantifying pld-1 protein levels